WO2003006032A1 - Pharmaceutical preparations for treatment or prophylaxis of arthritis urica - Google Patents
Pharmaceutical preparations for treatment or prophylaxis of arthritis urica Download PDFInfo
- Publication number
- WO2003006032A1 WO2003006032A1 PCT/DK2002/000464 DK0200464W WO03006032A1 WO 2003006032 A1 WO2003006032 A1 WO 2003006032A1 DK 0200464 W DK0200464 W DK 0200464W WO 03006032 A1 WO03006032 A1 WO 03006032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molybdenum
- treatment
- prophylaxis
- arthritis urica
- use according
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 13
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 12
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 32
- 239000011733 molybdenum Substances 0.000 claims abstract description 32
- 239000005078 molybdenum compound Substances 0.000 claims abstract description 18
- 150000002752 molybdenum compounds Chemical class 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011684 sodium molybdate Substances 0.000 description 2
- 235000015393 sodium molybdate Nutrition 0.000 description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Definitions
- the present invention is related to treatment and prophylaxis of arthritis urica in mammals, including human beings .
- Arthritis urica is a disorder of the purine metabolism in which inflammatory changes in joints are first of an acute type, but later becomes chronic. It is a characteristic feature that it is provoked by crystals of urate, conglomerates comprising such as well as precursors therefore.
- Arthritis urica affects approximately 0.2% of the adult population. The prevalence is nearly 10 times higher in men than in women. The most characteristic symptoms are recurrent painful inflammatory attacks involving a single joint and more permanent pains, often from several joints, which develop slowly after the debut of the first attack.
- the first attack most often affects a big toe and is then termed podagra.
- the disease has heriditable aspects and is often accompanied by an excess of uric acid in the blood.
- a concentration of urate in blood serum of more than 0.45 mmol/1 is regarded as hyperuricemia .
- Hyperuricemia is regarded as a condition for the occurence of arthritis urica but the majority of persons having hyperuricemia do not develop arthritis urica.
- Hyperuricemia may be due to an increased rate of synthesis of the purine precursors of the uric acid or to decreased elimination of uric acid by the kidneys, or to both.
- the medical treatment of arthritis urica has concentrated on alleviation of the acute attacks by administration of colchicine or a non-steroid anti- inflammatoric drug (NSAID) and a prophylactic or long-term treatment in which these drugs may also be used, and in which it is usual also to include a treatment of the hyperuricemia .
- the usual drugs are allopurinol, which reduces the production of uric acid, and probenecid, which increases the excretion of uric acid by the kindneys .
- colchicine in the dosage required for efficient treatment i.e. up to 6 mg per day, causes dyspepsia or diarrhoea in nearly half of the patients.
- the non-steroid anti-inflammatoric drugs must be administered at large dosages to be efficient. As it is well-known, also this type of drugs causes dyspepsia and may cause or aggreviate peptic ulcer. Allopurinol presents several adverse effects of which some are quite severe. Thus, besides dyspepsia, exanthema, and infections of the liver and bone marrow, it may cause severe vasculities having a substantial mortality. Probenecid has no effect if the function of the kidneys is reduced. This drug increases the risk of urolithiasis and also for this drug the side-effects comprise dyspepsia and exanthema.
- Molybdenum is an element which has been subjected to only moderate research within the pharmaceutical area. It is regarded as one of the essential trace elements and the recommended daily consumption for adults is 150-500 ⁇ g .
- molybdenum is mainly provided by milk and cereal products.
- This element forms part of a number of metallo- enzy es, such as aldehyde oxidates, and it has been established that lack of a co-factor necessary for the introduction of molybdenum in the metallo-enzymes causes neuro-logical affections and mental retarding.
- Molybdenum compounds are used as components in some vitamin and mineral tablets marketed as dietary supplement .
- molybdenum influences enzymatic processes partici- pating in metabolism of proteins involving formation of uric acid, a certain influence of molybdenum on arthritis urica were to be expected. However, since the influence of molybdenum on the total purine formation and metabolism processes is very complex, the net effect of an administration of molybdenum compounds to patients suffering from arthritis urica could not be foreseen.
- the present invention comprises use of a molybdenum-containing species for the manufacture of a pharmaceutical preparation for treatment or prophylaxis of arthritis urica.
- pharmaceutical preparation should be construed in its broadest sense as comprising not only all conventional solid, liquid or onctious pharmaceutical formulations but also compositions to be marketed as diet supplements or so-called functional -food products and food additives.
- the term is also intended as comprising implants in which molybdenum or molybdenum compounds are present in a slowly dissolving state for extended release.
- said molybdenum containing species is a molybdenum compound soluble in water to obtain a high and predictable bioavailability.
- Preferred water-soluble molybdenum compounds are salts in which the molybdenum is in oxidation step 6.
- alkaline metal molybdates which are stable and soluble in water.
- ammonium molybdate is very soluble in water.
- the pharmaceutical preparation produced is for oral adminis- tration, such as tablets, capsules, and pills, possibly for prolonged or delayed release of the active ingredient.
- Said formulations may also be effervescent to be easily dissolved or dispersed in water before administra- tion.
- granules are suitable.
- such preparations may contain one or more further active components or minerals, such as copper and iron, to compensate for possible increased excretion of such substances due to the molybdenum administration.
- Suitable formulations comprise sterile liquids for parenteral administration, such as injection liquids and infusion liquids, suppositories for rectal application and agents for transdermal application.
- a pharmaceutical preparation for oral administration is prepared as a unit dosage preparation containing a molybdenum compound in an amount corresponding to 10-500 ⁇ g molybdenum per unit. More preferably, such unit dosage preparations each contains a molybdenum compound in an amount corresponding to 20-200 ⁇ g molybdenum.
- the invention also comprises a pharmaceutical preparation for treatment or prophylaxis of arthritis urica, wherein an active component is a molybdenum species.
- said preparation is a unit dosage for oral administration containing a molybdenum compound in an amount corresponding to 10-500 ⁇ g molybdenum per unit.
- the invention comprises a therapeutical method of treating and/or preventing arthritis urica in which molybdenum is administered to a mammal suffering from this disease.
- the invention is further elucidated by means of the below report of trials.
- the table also comprises information whether the symptoms were mainly inflammatory attacks or permanent pain.
- Pre. Med is listed which prior prescribed medicine the patients received before start of the trial. The patients were instructed to continue taking this medicine until their condition were improved to such an extent that they felt they had no need for it any longer.
- the patients were instructed to take a number of drops of an aqueous solution of sodium molybdate corresponding to 75 ⁇ g molybdenum 3 times daily. Since some of the patients were in a state of malnutrition, they were also instructed to take a conventional vitamin/mineral tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Molybdenum, preferably as a molybdenum compound soluble in water, is used for the manufacture of a pharmaceutical preparation for treatment or prophylaxis of arthritis urica.
Description
Title: Pharmaceutical preparations for treatment or prophylaxis of arthritis urica.
Field of the invention The present invention is related to treatment and prophylaxis of arthritis urica in mammals, including human beings .
Arthritis urica, normally termed gout, is a disorder of the purine metabolism in which inflammatory changes in joints are first of an acute type, but later becomes chronic. It is a characteristic feature that it is provoked by crystals of urate, conglomerates comprising such as well as precursors therefore.
In connection with the present invention, it is important to distinguish this disease from other arthropathies, especially rheumatoid arthritis. Thus, a certain confusion often comes up, partly due to the fact that in some languages the same term is used for these two etiologically completely different diseases. Therefore, it is emphasized that the disease dealt with in the present specification and claims is proper arthritis urica provoked by a deposition of crystals of urate or uric acid in and around the joints and/or by precursors for urate or uric acid and/or by conglomerates comprising such.
Background of the invention
Arthritis urica affects approximately 0.2% of the adult population. The prevalence is nearly 10 times higher in men than in women. The most characteristic symptoms are recurrent painful inflammatory attacks involving a single joint and more permanent pains, often from several joints, which develop slowly after the debut of the first attack.
The first attack most often affects a big toe and is then termed podagra.
The disease has heriditable aspects and is often accompanied by an excess of uric acid in the blood. A concentration of urate in blood serum of more than 0.45 mmol/1 is regarded as hyperuricemia .
Hyperuricemia is regarded as a condition for the occurence of arthritis urica but the majority of persons having hyperuricemia do not develop arthritis urica.
Hyperuricemia may be due to an increased rate of synthesis of the purine precursors of the uric acid or to decreased elimination of uric acid by the kidneys, or to both.
Hitherto, the medical treatment of arthritis urica has concentrated on alleviation of the acute attacks by administration of colchicine or a non-steroid anti- inflammatoric drug (NSAID) and a prophylactic or long-term treatment in which these drugs may also be used, and in which it is usual also to include a treatment of the hyperuricemia . For this last-mentioned purpose, the usual drugs are allopurinol, which reduces the production of uric acid, and probenecid, which increases the excretion of uric acid by the kindneys .
Unfortunately, these conventional treatments are not always as efficient as desired, and all the above-mentioned drugs show side-effects (ADR = adverse drug reaction) , which put severe limits to their application or, in certain circumstances, prevent such.
Thus, colchicine in the dosage required for efficient treatment, i.e. up to 6 mg per day, causes dyspepsia or diarrhoea in nearly half of the patients.
The non-steroid anti-inflammatoric drugs must be administered at large dosages to be efficient. As it is well-known, also this type of drugs causes dyspepsia and may cause or aggreviate peptic ulcer. Allopurinol presents several adverse effects of which some are quite severe. Thus, besides dyspepsia, exanthema, and infections of the liver and bone marrow, it may cause severe vasculities having a substantial mortality. Probenecid has no effect if the function of the kidneys is reduced. This drug increases the risk of
urolithiasis and also for this drug the side-effects comprise dyspepsia and exanthema.
For both these two substances used against hyperuricemia, it applies that initially the administra- tion may provoke a new acute attack of arthritis urica.
Thus, there is a need for an efficient medicine for the treatment and prophylaxis of arthritis urica, not possessing the adverse side-effects of the drugs conventionally used for this purpose. Molybdenum is an element which has been subjected to only moderate research within the pharmaceutical area. It is regarded as one of the essential trace elements and the recommended daily consumption for adults is 150-500 μg .
In a normal diet, molybdenum is mainly provided by milk and cereal products.
This element forms part of a number of metallo- enzy es, such as aldehyde oxidates, and it has been established that lack of a co-factor necessary for the introduction of molybdenum in the metallo-enzymes causes neuro-logical affections and mental retarding.
It has also been described that a high consumption of molybdenum due to copper antagonism may result in copper deficiency and a syndrom similar to arthritis urica.
Molybdenum compounds are used as components in some vitamin and mineral tablets marketed as dietary supplement .
In 2 papers by H. Krzymien, viz. "Reumatologia" . 1970/8 (3) :193-8 and "Pol Tyg Lek" . 1973 Nov 12 ; 28 (46 : 1808- 10) , attempts to use molybdenum compounds for treatment of diseases different from arthritis urica are described. Thus, administration of ammonium molybdate in an amount corresponding to 0.15 g molybdenum daily to patients suffering from rheumatoid arthritis or Sjόgreen's syndrom caused a significant improvement. However, in said 2 papers, there is no suggestion or hint to try molybdenum in the treatment or prophylaxis of arthritis urica. Since molybdenum influences enzymatic processes partici-
pating in metabolism of proteins involving formation of uric acid, a certain influence of molybdenum on arthritis urica were to be expected. However, since the influence of molybdenum on the total purine formation and metabolism processes is very complex, the net effect of an administration of molybdenum compounds to patients suffering from arthritis urica could not be foreseen.
Summary of the invention It has now surprisingly been experienced that administration of molybdenum compounds to patients suffering from arthritis urica results in a rather fast occuring improvement of the condition of such patients.
Thus, in one aspect, the present invention comprises use of a molybdenum-containing species for the manufacture of a pharmaceutical preparation for treatment or prophylaxis of arthritis urica.
In the present specification and the attached claims the term pharmaceutical preparation should be construed in its broadest sense as comprising not only all conventional solid, liquid or onctious pharmaceutical formulations but also compositions to be marketed as diet supplements or so-called functional -food products and food additives. The term is also intended as comprising implants in which molybdenum or molybdenum compounds are present in a slowly dissolving state for extended release.
However, in the preferred embodiment of the invention, said molybdenum containing species is a molybdenum compound soluble in water to obtain a high and predictable bioavailability.
Preferred water-soluble molybdenum compounds are salts in which the molybdenum is in oxidation step 6.
Examples of such salts are alkaline metal molybdates, which are stable and soluble in water. Also ammonium molybdate is very soluble in water.
In the preferred use according to the invention, the pharmaceutical preparation produced is for oral adminis-
tration, such as tablets, capsules, and pills, possibly for prolonged or delayed release of the active ingredient.
Said formulations may also be effervescent to be easily dissolved or dispersed in water before administra- tion. For such purpose, also granules are suitable.
Besides conventional extenders and adjuvants, such preparations may contain one or more further active components or minerals, such as copper and iron, to compensate for possible increased excretion of such substances due to the molybdenum administration.
Other suitable formulations comprise sterile liquids for parenteral administration, such as injection liquids and infusion liquids, suppositories for rectal application and agents for transdermal application. In a preferred use according to the invention, a pharmaceutical preparation for oral administration is prepared as a unit dosage preparation containing a molybdenum compound in an amount corresponding to 10-500 μg molybdenum per unit. More preferably, such unit dosage preparations each contains a molybdenum compound in an amount corresponding to 20-200 μg molybdenum.
These ranges for preferred contents of molybdenum compound in the unit dosage preparations reflect the fact that, based on the experiences hitherto, an oral daily dosage of approximately 3 x 75 μg (calculated as molybdenum) is regarded as suitable, at least in the beginning of the treatment .
The surprising, beneficial effects of treatments using this low dosage of the molybdenum appear from the trials reported below.
No animal experiments have been conducted to establish the acute toxicity of the relevant molybdenum compounds. This is because such experiments are regarded as superfluous in view of the fact that the dosage used in connection with the present invention is approximately 600 times less than the dosage used for very prolonged treatments according to the two above-cited papers by H.
Krzymien. In said papers no adverse effects are reported, at least not in the abstracts.
The scope of the present invention is in no way restricted by any theoretical explanation as to the effect obtained. However, the fact that the improvement occurs substantially earlier than when a conventional anti- hyperuremic treatment is applied, sustains the following hypothesis :
In the metabolism of proteins, the following inter- mediates are formed:
proteins -> purines -> hypoxantin -> xantin -> uric acid.
In case of molybdenum insufficiency xantin oxidase is inhibited and thus the concentration of xantin (and hypoxantin) increases. Since xantin is less soluble than uric acid, it is assumed that precipitation of xantin takes place in an area near the affected joint. When a sufficient amount of molybdenum is supplied, a sufficient xantin oxidase acitivity is rather fast reestablished resulting in conversion of xantin into the more easily dissolving uric acid which is thus excreted.
The invention also comprises a pharmaceutical preparation for treatment or prophylaxis of arthritis urica, wherein an active component is a molybdenum species.
Preferably, said preparation is a unit dosage for oral administration containing a molybdenum compound in an amount corresponding to 10-500 μg molybdenum per unit.
Furthermore, the invention comprises a therapeutical method of treating and/or preventing arthritis urica in which molybdenum is administered to a mammal suffering from this disease.
The invention is further elucidated by means of the below report of trials.
Trials
12 patients having arthritis urica diagnosed more than 1 year before, and for most of them several years before the start of the trial, participated.
As it appears from the following table, said patients were domiciled in various parts of the world, for which reason their disease were hardly caused by local deficiencies in the diet.
The table also comprises information whether the symptoms were mainly inflammatory attacks or permanent pain.
Under the title, "Pre. Med." is listed which prior prescribed medicine the patients received before start of the trial. The patients were instructed to continue taking this medicine until their condition were improved to such an extent that they felt they had no need for it any longer.
The patients were instructed to take a number of drops of an aqueous solution of sodium molybdate corresponding to 75 μg molybdenum 3 times daily. Since some of the patients were in a state of malnutrition, they were also instructed to take a conventional vitamin/mineral tablet.
As it appears from the table, all 12 patients recovered to such an extent that their symptoms disap- peared, they could discontinue their previous medication and follow a normal drink and food pattern in contrast to the diet, which 9 of them previously felt necessary to avoid aggrevating their disease.
It should be observed that the improvement, as it appears, was manifest already within a couple of weeks.
The patients were instructed to continue the administration of the sodium molybdate drops after recovery. At the end of May 2001, no recrudescences were reported.
No..Ctry Age Sex Diag. Sympts . Symp . Diet Pre .Med. Treatment Improved Nil diet and yrs M/F year inflm.atta. perm. pain Yes/No begin condition no symptoms 0*
(t>
1 FR 70 1998 yes no yes Al 25.10.00 03.11.00 10.11.00 M
2 DK - M - yes no no lb 11.01.01 27.01.01 16.02.01
3 DK 57 M 1996 yes no no none 01.02.01 06.02.01 20.02.01
4 O 70 M 1995 yes yes yes Pr 11.02.01 17.02.01 16.03.01
5 US 65 M 1999 - yes yes Co, Id 22.02.01 09.03.01 30.04.01
6 GB 45 M 1990 yes yes yes In 09.03.01 25.03.01 05.05.01
7 AU 62 M 1974 yes yes yes Al, In 12.03.01 26.03.01 04.04.01
8 AU 45 M 1990 yes yes yes In 27.03.01 20.04.01 30.04.01
9 US 41 M 1994 yes yes yes Id, Co 08.04.01 19.04.01 15.05.01
10 US 56 F 1992 yes yes yes In 18.04.01 04.05.01 21.05.01
11 US 34 M 1998 yes yes yes Re, Ce 07.05.01 - 22.05.01
12 DK 53 M - yes yes - lb, Vo 01.05.01 30.05.01 ...
00
Prior Prescribed Medicine
Al Allopurinol
In Indomethacin
Pr Probecid
Co Colchicine
Id Indomethacin
Co Cortisone
Re Relefan
Ce Celebrex lb Ibuprofen
Vo Voltaren
Claims
P A T E N T C L A I M S 1. Use of a molybdenum species for the manufacture of a pharmaceutical preparation for treatment or prophylaxis of arthritis urica.
2. Use according to claim 1, wherein said species is a molybdenum compound soluble in water.
3. Use according to claim 2 , wherein said molybdenum compound is a salt, in which the molybdenum is in oxidation step 6.
4. Use according to claim 3, wherein said salt is selected from the group consisting of ammonium and alkaline metal molybdates.
5. Use according to anyone of the preceding claims, wherein the pharmaceutical preparation is for oral admin- istration.
6. Use according to claim 5, wherein the pharmaceutical preparation is a unit dosage preparation containing a molybdenum compound in an amount corresponding to 10-500 μg molybdenum per unit.
7. Use according to claim 5, wherein the unit dosage preparation contains a molybdenum compound in an amount corresponding to 20-200 μg molybdenum per unit.
8. Pharmaceutical preparation for treatment or prophylaxis of arthritis urica, c h a r a c t e r i z e d in containing a molybdenum species.
9. Pharmaceutical preparation according to claim 8, c h a r a c t e r i z e d in being a unit dosage for oral administration and containing a molybdenum compound in an amount corresponding to 20-200 μg molybdenum per unit.
10. Therapeutical treatment for alleviation or prophylaxis of arthritis urica comprising administration of molybdenum to a mammal suffering from said disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101107 | 2001-07-13 | ||
| DKPA200101107 | 2001-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003006032A1 true WO2003006032A1 (en) | 2003-01-23 |
Family
ID=8160626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DK2002/000464 WO2003006032A1 (en) | 2001-07-13 | 2002-07-03 | Pharmaceutical preparations for treatment or prophylaxis of arthritis urica |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2003006032A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2252729A (en) * | 1991-02-13 | 1992-08-19 | Bharat Sridhar Pancham | Vitamin- and/or mineral-containing pharmaceutical composition |
| RU2156087C1 (en) * | 1999-11-25 | 2000-09-20 | Товарищество с ограниченной ответственностью Фирма "Электронная медицина" | Biologically active addition |
-
2002
- 2002-07-03 WO PCT/DK2002/000464 patent/WO2003006032A1/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2252729A (en) * | 1991-02-13 | 1992-08-19 | Bharat Sridhar Pancham | Vitamin- and/or mineral-containing pharmaceutical composition |
| RU2156087C1 (en) * | 1999-11-25 | 2000-09-20 | Товарищество с ограниченной ответственностью Фирма "Электронная медицина" | Biologically active addition |
Non-Patent Citations (11)
| Title |
|---|
| ACTA VET. SCAND., vol. 22, no. 3-4, 1981, pages 289 - 295, ISSN: 0044-605x * |
| DATABASE MEDLINE [online] 12 November 1973 (1973-11-12), KRZYTMIEN H: "[Further therapeutic attempts at using molybdenum compounds in rheumatoid atrhritis]", XP002902700, retrieved from STN accession no. 74078223 Database accession no. nlm4771857 * |
| DATABASE MEDLINE [online] 1970, KRZYMIEN H: "[Attempts at treating rheumatoid arthritis and other chronic rheumatoid diseases with molybdenum compounds]", XP002902724, retrieved from STN accession no. 71004692 Database accession no. NLM5469424 * |
| DATABASE MEDLINE [online] 1984, LENER J ET AL: "Effects of molybdenum on the organism (a review).", XP002902725, retrieved from STN accession no. 85132602 Database accession no. NLM6396329 * |
| DATABASE MEDLINE [online] 1999, BARCELOUX D G: "Molybdenum.", XP002902726, retrieved from STN accession no. 199311567 Database accession no. NLM10382558 * |
| DATABASE STN INTERNATIONAL [online] FILE CAPLUS; KARRING M ET AL: "The influence of dietary molybdenum and copper supplementation on the contents of serum uric acid and some trace elements in cocks.", XP002902698, retrieved from STN accession no. 96:161272 Database accession no. 1982:161272 * |
| DATABASE STN INTERNATIONAL [online] FILE CAPLUS; SHOLOKHOV V M ET AL: "Biologically active addition.", XP002902699, retrieved from STN accession no. 135;343656 Database accession no. 2001:851947 * |
| JOURNAL OF HYGIENE, EPIDEMIOLOGY, MICROBIOLOGY, AND IMMUNOLOGY. CZECHOSLOVAKIA 1984, vol. 28, no. 4, 1984, pages 405 - 419, ISSN: 0022-1732 * |
| JOURNAL OF TOXICOLOGY. CLINICAL TOXICOLOGY. UNITED STATES 1999, vol. 37, no. 2, 1999, pages 231 - 237, ISSN: 0731-3810 * |
| POLSKI TYGODNIK LEKARSKI (WARSAW, POLAND: 1960), vol. 28, no. 46, 12 November 1973 (1973-11-12), pages 1808 - 1810, ISSN: 0032-3756 * |
| REUMATOLOGIA. POLAND 1970, vol. 8, no. 3, 1970, pages 193 - 198, ISSN: 0034-6233 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5932624A (en) | Vitamin supplement composition | |
| KR20000052687A (en) | Magnesium (-)Hydroxycitrate, Method of Preparation, Applications, and Compositions in Particular Pharmaceutical Containing Same | |
| BR112021006002A2 (en) | compositions for the reduction of serum uric acid | |
| JPWO2004019928A1 (en) | Liver disease treatment | |
| CA2421410C (en) | Iron compositions | |
| JP2019513382A (en) | Composition for the prevention, amelioration or treatment of hyperuricemia or hyperuricemia-related metabolic disorders, which comprises the extract of Yuchichi as an active ingredient | |
| US4387093A (en) | Arthritis treatment | |
| JPS62501846A (en) | liquid dietary calcium supplement | |
| Gibbs et al. | Biochemical studies on the treatment of primary hyperoxaluria | |
| KR101791034B1 (en) | Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Allii Radix as effective component | |
| JP2005537264A (en) | Composition for the treatment of peripheral neuropathy, its manufacture and use | |
| WO2003006032A1 (en) | Pharmaceutical preparations for treatment or prophylaxis of arthritis urica | |
| EP0218453A1 (en) | Improved antiinflammatory compositions and methods | |
| JPH08277221A (en) | Alcohol absorption inhibitor | |
| EP0551180B1 (en) | Use of bucillamine for the manufacture of a medicament for the treatment of cystinuria | |
| CN117425477A (en) | Pharmaceutical composition comprising 1- (3-cyano-1-isopropyl-indol-5-yl) pyrazole-4-carboxylic acid | |
| CN107106623A (en) | The mixed extract for containing camomile and cassia bark as active ingredient the composition for being used to suppress gout | |
| WO2006064744A1 (en) | Medicinal composition for treating diabetes | |
| KR20040010666A (en) | Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | |
| JP7550054B2 (en) | Agent for suppressing intoxication or hangover caused by alcoholic beverage intake | |
| JP6112767B2 (en) | Composition for lowering uric acid level in blood | |
| JPS625923A (en) | Remedy for allergic disease | |
| JPH05501405A (en) | Phosphate binder for oral administration | |
| TO et al. | Metabolic Aspects and Medical Treatment for Urinary Tract Stones | |
| JP2019504870A (en) | Use of stilipentol and its derivatives to reduce urinary oxalate concentrations in individuals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |